Rejected from Cell Reports? The 7 Best Journals to Submit Next

• "The experimental evidence doesn't fully support the conclusions.": Cell Reports reviewers flag overstatement, missing controls, or gaps in the experimental logic. This is the most actionable type of rejection because the problems are fixable.

• "The advance is too incremental.": Your paper refines existing knowledge but doesn't change understanding meaningfully. Even at ~14% acceptance, Cell Reports wants papers that advance the field, not just add data points.

• "The paper would benefit from additional experiments.": Cell Reports, unlike Cell or Molecular Cell, doesn't typically ask for 6 months of additional work. But if reviewers felt key experiments were missing, the editor may have decided the gap was too large.

• "The topic is better suited to a specialty journal.": Your biology is solid but very specialized. A developmental biology finding, for example, may be better served by Development or Developmental Cell.

Before choosing your next journal, a Cell Reports manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Rejected for "insufficient novelty"?: eLife (transparent review) or PNAS (values rigor over novelty) or your field's top journal.

• Rejected for experimental gaps?: Fix the gaps before resubmitting. Cell Reports reviewers are relatively specific about what's missing.

• Rejected for scope?: Go to your field-specific journal. It's a better fit, not a step down.

PLOS Biology publishes biological research with broad implications and a commitment to open science. If Cell Reports rejected for insufficient novelty, PLOS Biology may value other aspects of your work: reproducibility, open data, or methodological rigor.

Best for: Biology with broad implications, open-science-focused research, and reproducibility-focused studies.

eLife publishes your paper with reviews attached, letting the community judge the work. For papers where Cell Reports' editorial decision felt subjective, eLife's transparent model provides a different evaluation framework.

Best for: Biology papers where you want transparency and community judgment.

EMBO Reports publishes concise molecular biology papers with functional insight. If your Cell Reports submission was a biology paper with clear conclusions but not enough experimental breadth for Cell Reports, EMBO Reports' shorter-format requirement may actually work in your favor.

Best for: Concise molecular biology, gene regulation, cell signaling, and cell biology findings.

PNAS publishes across all sciences with a ~15% acceptance rate . For biology papers that Cell Reports found too incremental, PNAS may value the rigor and completeness differently. PNAS is particularly strong for papers that cross traditional discipline boundaries.

Best for: Rigorous biology across all subfields, interdisciplinary biological research.

If your paper is strong enough for Cell Reports (IF ~7) but got rejected, Nature Communications (IF ~16) might seem ambitious, but its ~8% acceptance rate means the competition is similar.

Best for: Strong biological research that needs a broad-scope, high-impact home.

JCB is published by Rockefeller University Press and focuses specifically on cell biology. If your paper is cell biology research that Cell Reports found too specialized, JCB provides a dedicated audience of cell biologists.

Best for: Cell biology specifically: membrane biology, organelle function, cell division, cytoskeleton, cell migration.

If Cell Reports rejected for scope, go to the top journal in your field. Development for developmental biology, Plant Cell for plant biology, Journal of Immunology for immunological research. These journals' editors know the field context better than generalist editors, and they reach the audience that will actually use your findings. Don't think of a specialty journal as a step down from Cell Reports. A paper in Development (IF ~4) read by every developmental biologist is often more impactful than a paper in Cell Reports (IF ~7) that developmental biologists might miss among the hundreds of papers across all fields published there each year.

Best for: Papers where the contribution is primarily important within one biological subfield.

The main question after a Cell Reports rejection is whether the paper needs more experimentation or just a better-matched audience.

If the reviewers were mainly asking for one missing control, one missing comparison, or a cleaner causal chain, it is usually worth fixing that before you move. If the core message was that the paper is simply too specialized for a broad-biology venue, then the better move is to stop shopping laterally and pick the field journal whose readers already care about the specific mechanism, assay, or biological system.

That distinction matters more than the prestige ladder. The best next journal is the one where the existing manuscript is easiest to evaluate fairly.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting Cell Reports, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Figure quality or experimental completeness concerns visible at the desk. Cell Reports uses professional editors who screen figure quality and experimental completeness before assigning peer review. We see this failure as the most common pattern in Cell Reports desk rejections we review: missing quantification panels on western blots, inconsistent sample sizes across figure panels, unclear or absent statistical tests, or Figure 1 that does not establish the basic biology before the paper's main claims are introduced. In our review of Cell Reports submissions, we find that editors consistently return papers where the experimental foundation is unclear from the figures before the story can be evaluated.

Scope too narrow for a broad biology readership. Cell Reports publishes cell biology, neuroscience, developmental biology, cancer biology, and immunology for a cross-disciplinary audience. Papers where the central finding is significant only to specialists in one narrow subfield consistently fail the desk breadth test. We see this pattern in Cell Reports submissions we review present excellent mechanistic data in a specific disease context or model system where the broader relevance to Cell Reports' general biology readership is not established.

Mechanistic story incomplete relative to Cell Reports' standards. Cell Reports occupies a middle tier in the Cell Press portfolio, publishing work that is solid and complete but not necessarily transformative. We see this pattern in Cell Reports submissions we review present incomplete mechanistic stories: a phenotype is demonstrated without its mechanism, or a mechanism is proposed without rescue or epistasis experiments that would confirm the causal chain. Editors return these with requests to complete the story before the paper can be evaluated.

Replicate numbers or statistical power insufficient for the conclusions drawn. Cell Reports editors screen for n values and statistical rigor at the desk. We see this failure regularly in manuscripts we review: papers where n=3 biological replicates are presented for central claims without justification, or where the statistical test choice is mismatched to the data distribution.

SciRev community data for Cell Reports confirms desk rejections typically arrive within days, with post-review first decisions within 4-6 weeks, consistent with the Cell Press editorial cadence for its broad-scope portfolio journals.